Biomerica, Inc. (BMRA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BMRA Revenue Growth
Revenue Breakdown (FY 2021)
BMRA's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
By Geography
BMRA Revenue Analysis (2014–2025)
As of May 9, 2026, Biomerica, Inc. (BMRA) generated trailing twelve-month (TTM) revenue of $4.5 million, reflecting significant decline in growth of -26.0% year-over-year. The most recent quarter (Q2 2026) recorded $1.2 million in revenue, down 12.3% sequentially.
Looking at the longer-term picture, BMRA's 5-year compound annual growth rate (CAGR) stands at -4.5%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $18.9 million in 2022.
Revenue diversification analysis shows BMRA's business is primarily driven by ClinicalLabMember (43%), PhysiciansOfficeMember (39%), and OverthecounterMember (11%).
When compared to Healthcare sector peers including CODX (-83.2% YoY), QDEL (-3.9% YoY), and OSUR (-47.3% YoY), BMRA has underperformed the peer group in terms of revenue growth. Compare BMRA vs CODX →
BMRA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BMRACurrent | $4M | -26.0% | -4.5% | -96.7% | |
 CODX | $622,489 | -83.2% | -61.6% | -5025.5% | |
 QDEL | $2.7B | -3.9% | +10.4% | -33.7% | |
 OSUR | $115M | -47.3% | -7.7% | -59.2% | |
 HOLX | $4.1B | +2.2% | +1.7% | 17.4% | |
 BIO | $2.6B | +1.9% | +0.3% | 10.5% |
BMRA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.3M | -1.9% | $498K | 9.4% | $-5,137,000 | -96.7% |
| 2024 | $5.4M | +1.4% | $611K | 11.3% | $-6,367,000 | -117.6% |
| 2023 | $5.3M | -71.7% | $446K | 8.4% | $-7,223,000 | -135.3% |
| 2022 | $18.9M | +162.1% | $3.0M | 15.8% | $-4,533,964 | -24.0% |
| 2021 | $7.2M | +7.6% | $366K | 5.1% | $-7,499,693 | -104.2% |
| 2020 | $6.7M | +28.7% | $1.8M | 26.6% | $-2,402,848 | -35.9% |
| 2019 | $5.2M | -6.5% | $1.3M | 24.8% | $-2,412,790 | -46.4% |
| 2018 | $5.6M | -3.9% | $1.8M | 31.5% | $-1,481,755 | -26.6% |
| 2017 | $5.8M | +12.7% | $2.0M | 34.9% | $-954,633 | -16.5% |
| 2016 | $5.1M | +3.6% | $1.5M | 29.7% | $-826,952 | -16.1% |
See BMRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBMRA — Frequently Asked Questions
Quick answers to the most common questions about buying BMRA stock.
Is BMRA's revenue growth accelerating or slowing?
BMRA revenue declined -26.0% year-over-year, contrasting with the 5-year CAGR of -4.5%. TTM revenue fell to $4M. This reverses the prior growth trend.
What is BMRA's long-term revenue growth rate?
Biomerica, Inc.'s 5-year revenue CAGR of -4.5% reflects the variable expansion pattern. Current YoY growth of -26.0% is below this long-term average.
How is BMRA's revenue distributed by segment?
BMRA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.